
pmid: 31023742
In this issue of Blood, Howard et al report a phase 1/2 study of voxelotor (GBT440) in sickle cell anemia. This drug binds to the α-globin chain of hemoglobin and increases hemoglobin-oxygen affinity, thereby decreasing the polymerization tendency of deoxygenated sickle hemoglobin (HbS). Treated patients had a median 1 g/dL increase of hemoglobin concentration, and markers of hemolysis were decreased.1
Patients, Benzaldehydes, Pyrazines, Humans, Pyrazoles, Anemia, Sickle Cell, Polymerization
Patients, Benzaldehydes, Pyrazines, Humans, Pyrazoles, Anemia, Sickle Cell, Polymerization
| citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 3 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
